Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TPM3
REST API REST API
Homo sapiens
TPM3 is differentially expressed in 237 experiments: 146 organism parts: lung, bone marrow, ... (144 more);, 227 disease states: normal, control, ... (225 more);, 73 cell types 341 cell lines 26 compound treatments and 73 other conditions.
Synonyms TRK, NEM1
Orthologs TPM1 (Saccharomyces cerevisiae)   TPM3 (Gallus gallus)   TPM3_BOVIN (Bos taurus)   Tpm3 (Mus musculus)   tpm3 (Danio rerio)   TPM2 (Saccharomyces cerevisiae)   Tm2 (Drosophila melanogaster)   Tm1 (Drosophila melanogaster)   tpm3 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytosol, cleavage furrow, cytoskeleton, cytoplasm, cellular component movement, molecular_function, neuron projection, actin cytoskeleton, cortical cytoskeleton, muscle contraction, regulation of muscle contraction, growth cone, filamentous actin, actin binding, stress fiber, muscle filament sliding, podosome, muscle thin filament tropomyosin
InterPro Term Tropomyosin
UniProt Accession Q6LDX7, D6R904, D6RGJ6, D6RFM2, Q5VU61, Q5VU62, Q5VU66, Q5VU63, Q5VU72, Q5VU59, Q5VU58, Q8TCG3, B4DWT5, Q8NI98, P06753
Gene-Disease Assocation THYROID CARCINOMA, PAPILLARY, NEMALINE MYOPATHY 1; NEM1
Search EB-eye ENSG00000143549
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-MEXP-1251, E-GEOD-1577, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (31 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
K562
2
E-GEOD-24147, E-MTAB-37
SW480
2
E-MEXP-1014, E-GEOD-18005
SW620
2
E-MEXP-1014, E-MTAB-37
MDA-MB-231
1
2
E-TABM-420, E-GEOD-5823, E-MTAB-62
335 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, E-GEOD-13987, ... (37 experiments)

Factor Value U/D Experiments
CXCR4 positive
1
E-GEOD-15893
CD34+ hematopoietic stem cell
1
E-MEXP-1546
human foreskin fibroblast
1
E-GEOD-18265
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
induced pluripotent stem cell
1
E-GEOD-18265
centroblast
1
E-TABM-702
67 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (49 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62
myeloma
2
E-MTAB-37, E-MTAB-62
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1007
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
221 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-MEXP-1958, ... (18 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-412, E-MEXP-1601, E-GEOD-5824, E-MEXP-1958, E-GEOD-20719, ... (9 experiments)
AMP
1
1
E-MEXP-2285
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
unknown
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
TNF
1
E-GEOD-15205
20 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-GEOD-21138

Environmental stress
studied in E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-TABM-321, E-TABM-868, E-TABM-601, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-22152, E-GEOD-1460, E-GEOD-17636

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Race
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.252 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM